The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer; Takeda
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; GlaxoSmithKline; MSD Oncology; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; MSD Oncology; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Emilio Esteban
Travel, Accommodations, Expenses - Pfizer/EMD Serono; Pfizer/EMD Serono
 
Giovanna Speranza
Research Funding - MSD (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - EMD Serono (Inst); Merck (Inst)
 
Maximilian J. Hochmair
No Relationships to Disclose
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Vyriad (Inst)
 
Susanna Y. Cheng
Honoraria - AstraZeneca; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Merck
 
Helge Bischoff
Research Funding - MSD (Inst)
 
Nir Peled
Consulting or Advisory Role - Advisor & Honorarium for AZ, BI, BMS, Lilly , MSD, Novartis, pfizer, Roche
Speakers' Bureau - Advisor & Honorarium for AZ, BI, BMS, Lilly , MSD, Novartis, pfizer, Roche
 
Rina Hui
Honoraria - Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); MSD Oncology (Inst)
 
Edward B. Garon
Consulting or Advisory Role - Dracen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Michael J. Boyer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Benitec Biopharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck Sharp & Dohme
 
Jing Yang
Employment - Merck
 
Maria Catherine Pietanza
Employment - Merck
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche